Electric Tumor Treatment Fields — CPB 0827 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0827 covering electric tumor treatment fields, effective February 19, 2026. Billing teams need to confirm nine medical necessity criteria before submitting E0766 and A4555 claims — and plan for mandatory re-authorization every 90 days.

Quick-Reference Table

Aetna Electric Tumor Treatment Fields Coverage Criteria and Medical Necessity Requirements 2026

The Aetna electric tumor treatment fields coverage policy under CPB 0827 Aetna system is one of the tighter prior authorization frameworks in oncology billing. All nine criteria must be met — not most of them, all of them. If one falls short, the claim won't hold up.

Here's what Aetna requires for E0766 (electrical stimulation device used for cancer treatment) and A4555 (electrode/transducer replacement) to be covered:

That seven-week timing window is where claims break down most often. Make sure your clinical team documents the exact date of the last chemo or radiation dose — not an approximation. Aetna will ask.

Also bill CPT 1025T (alternating electric fields dosimetry and delivery-simulation modeling) and the temozolomide codes J8700 (oral, 5 mg) and J9328 (injection, 1 mg) only when they align with covered treatment. These codes all require the same selection criteria to be satisfied.

Continued coverage requires re-authorization every 90 days. No sooner than day 60 and no later than day 91 after starting therapy, the treating practitioner must conduct an in-person clinical re-evaluation. That evaluation must document that the member is still using and benefiting from TTFT. Objective evidence of adherence — meaning device data showing 18 hours per day average use — is required. Miss that window, and coverage lapses.

This 60-to-91-day re-evaluation window is strict. Build it into your scheduling system now. A claim denial at month four because your team missed the re-auth window is avoidable — and expensive.

Aetna Electric Tumor Treatment Fields Exclusions and Non-Covered Indications

Aetna's coverage policy here is narrow by design. TTFT is covered for one diagnosis — newly diagnosed glioblastoma — and that's it. Everything else is classified as experimental, investigational, or unproven.

Other tumor types are not covered. Aetna explicitly calls out breast cancer, lung cancer, melanoma, non-small cell lung cancer, osteosarcoma, ovarian cancer, pleural mesothelioma, pancreatic cancer, and solid tumor brain metastases. Salivary gland tumors — including parotid adenoid cystic carcinoma — are also on the exclusion list. This is not a complete list; it's illustrative. If it isn't newly diagnosed supratentorial glioblastoma, don't submit E0766 expecting coverage.

Combination therapies with agents other than temozolomide are not covered. Aetna excludes ETTF combined with bevacizumab, lomustine, paclitaxel, cisplatin, cyclophosphamide, doxorubicin, pemetrexed, and others. J8700 and J9328 cover temozolomide specifically. Any other combination drug regimen paired with TTFT falls outside this coverage policy.

The ICD-10 codes associated with this policy — 163 total — span a wide range of malignancies, from C08.x (salivary gland) to C25.x (pancreas) to C33–C34.92 (lung). These appear in the policy as non-covered diagnoses. If you're seeing these codes on orders for TTFT, stop before submitting. They map to the experimental/investigational bucket, not the covered bucket.

Coverage Indications at a Glance

Aetna Electric Tumor Treatment Fields Billing Guidelines and Action Items 2026

Electric tumor treatment fields billing under this updated policy has real financial exposure. The device (E0766) is durable medical equipment — that means ongoing monthly claims, and every one of them can be audited against these criteria. Here's what to do before February 19, 2026.

The reimbursement at stake here is significant. TTFT is a monthly DME rental — these aren't one-time claims. Getting the authorization framework right from day one protects revenue across the full treatment course, which can run many months.

CPT, HCPCS, and ICD-10 Codes for Electric Tumor Treatment Fields Under CPB 0827

Covered CPT Codes (When Selection Criteria Are Met)

Covered HCPCS Codes (When Selection Criteria Are Met)

Key ICD-10-CM Diagnosis Codes (Non-Covered / Experimental Indications)

These codes appear in CPB 0827 and map to the experimental/investigational designation. Do not bill E0766 against these diagnoses.

The full policy lists 163 ICD-10-CM codes across multiple malignancy categories. Review the complete code list at the source policy before assuming a diagnosis qualifies.